Ancora Advisors LLC Has $4.46 Million Holdings in Pfizer Inc. (NYSE:PFE)

Ancora Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 32.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 168,234 shares of the biopharmaceutical company's stock after selling 79,467 shares during the quarter. Ancora Advisors LLC's holdings in Pfizer were worth $4,463,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PFE. Versant Capital Management Inc boosted its stake in Pfizer by 53.3% during the 4th quarter. Versant Capital Management Inc now owns 6,799 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 2,365 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in Pfizer by 95.1% during the fourth quarter. Central Pacific Bank Trust Division now owns 18,118 shares of the biopharmaceutical company's stock valued at $481,000 after buying an additional 8,832 shares in the last quarter. Nordea Investment Management AB grew its holdings in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the period. Pensionfund Sabic raised its position in Pfizer by 41.7% in the fourth quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company's stock worth $2,255,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Neville Rodie & Shaw Inc. lifted its holdings in Pfizer by 8.7% in the 4th quarter. Neville Rodie & Shaw Inc. now owns 104,728 shares of the biopharmaceutical company's stock valued at $2,779,000 after acquiring an additional 8,365 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 1.4 %

Shares of NYSE:PFE traded down $0.34 during midday trading on Monday, hitting $23.86. 40,532,428 shares of the stock were exchanged, compared to its average volume of 40,491,431. The company has a market capitalization of $135.32 billion, a PE ratio of 16.92, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business's fifty day simple moving average is $24.29 and its two-hundred day simple moving average is $25.69.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the company earned $0.82 EPS. The firm's revenue was down 7.8% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.21%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.